Literature DB >> 29182165

Me too-drugs with limited benefits - the tale of regorafenib for HCC.

Bishal Gyawali, Vinay Prasad.   

Abstract

This corrects the article DOI: 10.1038/nrclinonc.2017.100.

Entities:  

Year:  2017        PMID： 29182165     DOI： 10.1038/nrclinonc.2017.190

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  1 in total

1.  Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.

Authors:  Bishal Gyawali; Vinay Prasad
Journal:  Nat Rev Clin Oncol       Date:  2017-07-18       Impact factor: 66.675
  1 in total
  3 in total

1.  Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells.

Authors:  Man Wu; Guanren Zhao; Xiaomei Zhuang; Tianhong Zhang; Ce Zhang; Wenpeng Zhang; Zhenqing Zhang
Journal:  Onco Targets Ther       Date:  2018-05-18       Impact factor: 4.147

2.  Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.

Authors:  Amir Shlomai; Moshe Leshno; Daniel A Goldstein
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

Review 3.  Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment.

Authors:  Ruyin Chen; Qiong Li; Shuaishuai Xu; Chanqi Ye; Tian Tian; Qi Jiang; Jianzhen Shan; Jian Ruan
Journal:  Cancer Cell Int       Date:  2022-02-11       Impact factor: 5.722
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.